Aims: For several types of cancer, including colon cancer, the survival gap between middle-aged patients and elderly patients widened between 1988 and 1999 in Europe. The aim of our study was to describe treatments and compare survival rates over time (1991-2005) between middle-aged (<65 years), aged (65-74 years) and elderly (≥ 75 years) colon cancer patients in the mid-western part of the Netherlands to assess whether this survival gap further increased.
Methods: All 8926 patients with invasive colon cancer diagnosed between 1991 and 2005 were selected from the Comprehensive Cancer Centre West. Relative survival was calculated. Relative Excess Risks of death (RER) were estimated using a multivariable generalized linear model with a Poisson distribution.
Results: There were no significant changes in the treatment for stage I and II colon. Patients with stage III and IV more often received chemotherapy over time (from 9.6% to 54.3% and from 7.5% to 44.2% for all ages, respectively), while less stage IV patients were operated on (from 73.1% to 55.2%). Relative 5-year survival increased significantly for middle-aged patients (RER = 0.97, 95%CI = 0.95-0.98, p < 0.001), borderline significantly (RER = 0.98, 95%CI = 0.97-0.99, p = 0.05) for elderly patients and not significantly for aged patients (RER = 0.99, 95%CI = 0.97-1.00, p = 0.08) after adjustment for sex, age, grade, stage, and treatment.
Conclusions: The survival gap earlier found by the EUROCARE is confirmed for the mid-western part of the Netherlands, even after adjustment for age, sex, grade, stage and treatment. However, present study does not show an increase in the survival gap between middle-aged and elderly patients.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.ejso.2011.06.013 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
[Disease burden of communicable diseases among children and adolescents aged under 20 years in China from 1990 to 2021].
Zhongguo Dang Dai Er Ke Za Zhi
January 2025
Department of Pediatrics, Third Xiangya Hospital of Central South University, Changsha 410013, China.
Objectives: To investigate the epidemiological characteristics and changing trends of communicable diseases among children and adolescents in China from 1990 to 2021.
Methods: Based on the Global Burden of Disease Database, epidemiological indicators for communicable diseases among the population aged under 20 years in China from 1990 to 2021 were selected to analyze the burden of communicable diseases in this population, and a comparative analysis was performed with global data as well as data from Western Europe and North America.
Results: In 1990-2021, the overall burden of communicable diseases tended to decrease among children and adolescents in China.
Retrospective modelling of the disease and mortality burden of the 1918-1920 influenza pandemic in Zurich, Switzerland.
Epidemics
January 2025
Institute of Evolutionary Medicine, University of Zurich, Switzerland; Swiss School of Public Health SSPH+, Zurich, Switzerland; Crisis Competence Center, University of Zurich, Switzerland. Electronic address:
Background: Our study aims to enhance future pandemic preparedness by integrating lessons from historical pandemics, focusing on the multidimensional analysis of past outbreaks. It addresses the gap in existing modelling studies by combining various pandemic parameters in a comprehensive setting. Using Zurich as a case study, we seek a deeper understanding of pandemic dynamics to inform future scenarios.
View Article and Find Full Text PDFIntroduction: Organ donation refers to the collection of a human organ from a living or deceased donor and its transplantation into a recipient. An organ transplant recipient is a patient with organ failure who will not survive unless he receives a new organ. Although the benefits of organ transplantation are undeniable, there is a significant gap between the number of donors and recipients, as the demand for organs greatly surpasses the available supply.
View Article and Find Full Text PDFManagement of Recurrent Clostridioides difficile Infection (rCDI): A Systematic Literature Review to Assess the Feasibility of Indirect Treatment Comparison (ITC).
Infect Dis Ther
January 2025
Global Research and Medical, Ferring Pharmaceuticals, Kastrup, Denmark.
Recurrent Clostridioides difficile infection (rCDI) is a major cause of increased morbidity, mortality, and healthcare costs. Fecal-microbiota-based therapies are recommended for rCDI on completion of standard-of-care (SoC) antibiotics to prevent further recurrence: these therapies include conventional fecal-microbiota transplantation and the US Food and Drug Administration-approved therapies REBYOTA® (RBL) and VOWST Oral Spores™ (VOS). As an alternative to microbiota-based therapies, bezlotoxumab, a monoclonal antibody, is used as adjuvant to SoC antibiotics to prevent rCDI.
View Article and Find Full Text PDFIncreased mortality risk in people with schizophrenia in Lithuania 2001-2020.
Schizophrenia (Heidelb)
January 2025
Laboratory of Cancer Epidemiology, National Cancer Institute, Vilnius, Lithuania.
The aim of this study was to assess mortality risk in people with schizophrenia in Lithuania from 2001 and 2020. Cause-specific and all-cause mortality risk among patients with schizophrenia was assessed using a retrospective cohort study design. The cohort identified all patients with schizophrenia diagnosis (ICD-10 code F20) who were admitted to the Vilnius Republican Psychiatric Hospital from 1 January, 2001 to December 31, 2020.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!